Literature DB >> 1466253

Do estrogens improve bone mineral density in osteoporotic women over age 65?

C W Marx1, G E Dailey, C Cheney, V C Vint, D B Muchmore.   

Abstract

A retrospective analysis of our experience with estrogen and fluoride treatment in 91 patients with postmenopausal osteopenia followed for 6-47 months has been performed. Treatment included calcium (1000 mg/day) and either conjugated estrogens (0.625 mg/day) or sodium fluoride (50 mg/day), or both. All patients had at least two serial dual-photon spinal bone mineral density measurements performed 6 months or more apart. Estrogen treatment was associated with increased bone mineral density (5.3%/year), as was fluoride alone (7.5%/year). Estrogen and fluoride together were additive (9.6%/year). In women over age 65 the estrogen effect was just as great (6.9%/year) as in younger women. Estrogen benefit occurred predominantly in the first 18 months of treatment (7.0%/year), after which time changes in bone mineral density were similar to those in untreated controls, who showed stable bone mineral density. We conclude that aggressive estrogen and fluoride treatment tailored to the severity of the individual's postmenopausal osteopenia results in short-term improvement in spinal bone mineral density. These data further support that elderly women respond to estrogen replacement therapy with absolute and relative increments in bone density similar to those in younger women.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466253     DOI: 10.1002/jbmr.5650071122

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats.

Authors:  F Bauss; A Esswein; K Reiff; G Sponer; B Müller-Beckmann
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

2.  Can the effects of exercise on bone quality be detected using the CUBA clinical ultrasound system?

Authors:  N Messenger; S Scott; P McNaught-Davis
Journal:  Br J Sports Med       Date:  1998-06       Impact factor: 13.800

3.  Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist and total body in late postmenopausal women.

Authors:  W M Kohrt; S J Birge
Journal:  Osteoporos Int       Date:  1995-05       Impact factor: 4.507

4.  Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

Authors:  S Adami; L Bufalino; R Cervetti; C Di Marco; O Di Munno; L Fantasia; G C Isaia; U Serni; L Vecchiet; M Passeri
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  Does the French general practitioner correctly investigate and treat osteoporosis? Groupe Rhumatologique d'Etudes Cliniques de Midi-Pyrénées.

Authors:  M Laroche; B Mazières
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Age-related changes in human oestrogen receptor alpha function and levels in osteoblasts.

Authors:  M A Ankrom; J A Patterson; P Y d'Avis; U K Vetter; M R Blackman; P D Sponseller; M Tayback; P G Robey; J R Shapiro; N S Fedarko
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

7.  Comparative anti-osteoporotic properties of the leaves and roots of Marantodes pumilum var. alata in postmenopausal rat model.

Authors:  Tijjani Rabiu Giaze; Ahmad Nazrun Shuid; Ima Nirwana Soelaiman; Norliza Muhammad; Jamia Azdina Jamal; Mh Busra Fauzi; Norazlina Mohamed
Journal:  J Tradit Complement Med       Date:  2019-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.